Uppsala, Sweden – June 29, 2018 – The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15, 2018.
Today, the last trading day of the month, there are in total 35,450,456 shares - whereof 34,560,456 are ordinary shares and 890 000 class C shares - and 34,649,456 votes in the company.
For further information, please contact:
Orexo AB (publ.)
|Henrik Juuel, EVP and CFO||Lena Wange, IR & Communications Manager|
|Tel: +46 (0)18 780 88 00||Tel: +46 (0)18 780 88 00|
|E-mail: firstname.lastname@example.org||E-mail: email@example.com|
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
This information is information that Orexo AB (publ.) is obliged to make public in accordance with the Swedish Financial Instruments Trading Act. The information was submitted for publication at 6.00 pm CET on June 29, 2018